FDA schedules March ODAC for Geron’s MDS drug following PhIII data

Bay Area biotech Geron’s stock dipped slight­ly Mon­day af­ter the FDA an­nounced an On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee for the com­pa­ny’s ex­per­i­men­tal drug ime­tel­stat.

Ime­tel­stat is an in­jectable drug de­signed to treat adult pa­tients with ane­mia who are de­pen­dent on trans­fu­sions, and who al­so have myelodys­plas­tic syn­dromes (MDS). The com­pa­ny has ap­plied for ap­proval in pa­tients who have failed to re­spond, or have lost re­sponse to, or are in­el­i­gi­ble for ery­thro­poiesis-stim­u­lat­ing treat­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.